Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI trimmed its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 22.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 29,011 shares of the medical instruments supplier's stock after selling 8,477 shares during the quarter. Becton, Dickinson and Company comprises 1.2% of Arcadia Investment Management Corp MI's investment portfolio, making the stock its 27th biggest position. Arcadia Investment Management Corp MI's holdings in Becton, Dickinson and Company were worth $6,645,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $27,000. REAP Financial Group LLC lifted its holdings in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the last quarter. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. Picton Mahoney Asset Management increased its stake in Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares during the period. Finally, Nexus Investment Management ULC purchased a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $34,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company downgraded shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price on the stock. in a research note on Friday, May 2nd. Citigroup downgraded shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their target price for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their target price for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Finally, William Blair downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $219.22.

Becton, Dickinson and Company Stock Up 1.1%

Shares of Becton, Dickinson and Company stock traded up $1.86 during trading hours on Thursday, hitting $177.36. The company had a trading volume of 3,014,067 shares, compared to its average volume of 2,075,925. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The company's 50-day moving average is $172.19 and its two-hundred day moving average is $206.41. The company has a market cap of $50.83 billion, a P/E ratio of 33.85, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.17 earnings per share. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.35%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.

Insider Activity

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.